BIOLIFE SOLUTIONS, INC. (NASDAQ:BLFS) Files An 8-K Other EventsItem 8.01 Other Events.
On October 30, 2017,BioLife Solutions, Inc. (the“Company”) issued a press release announcing that the Company had received an aggregate of $1.9 million from the exercise of outstanding warrants. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| 99.1 | Press Release dated October 30, 2017 |
BIOLIFE SOLUTIONS INC ExhibitEX-99.1 2 tv477948_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 BioLife Solutions Receives $1.9 Million from Exercise of Warrants BOTHELL,…To view the full exhibit click here
About BIOLIFE SOLUTIONS, INC. (NASDAQ:BLFS)
BioLife Solutions, Inc. (BioLife) is engaged in the developing, manufacturing and marketing a portfolio of biopreservation tools and services for cells, tissues and organs, including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management application for shippers. The Company’s product offerings include hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs; generic blood stem cell freezing and cell thawing media products; custom product formulation and custom packaging services; cold chain logistics services incorporating precision thermal packaging products and cloud-hosted Web applications, and contract aseptic manufacturing formulation, fill and finish services of liquid media products. Its products include HypoThermosol FRS, CryoStor, BloodStor, Cell Thawing Media, PrepaStor and biologistex cold-chain management service.
